Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
María Luisa Antelo, Natalia de las Heras, Jose Ramón Gonzalez Porras, Ana Kerguelen & Jose María Raya. (2015) Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. Expert Review of Hematology 8:6, pages 819-835.
Read now
Read now
Chad C Cherington, Krisstina L Gowin & Ruben A Mesa. (2015) Ruxolitinib for treatment of polycythemia vera. Expert Opinion on Orphan Drugs 3:9, pages 1085-1096.
Read now
Read now
Articles from other publishers (18)
Seug Yun Yoon & Sung-Yong Kim. (2023) Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms. The Korean Journal of Internal Medicine 38:6, pages 810-817.
Crossref
Crossref
Sung-Yong Kim. (2023) Adverse effects of hydroxyurea used for the treatment of myeloproliferative neoplasms. Journal of the Korean Medical Association 66:4, pages 253-257.
Crossref
Crossref
Jie Jin, Albert Qin, Lei Zhang, Weihong Shen, Wei Wang, Jingjing Zhang, Yaning Li, Daoxiang Wu & Zhijian Xiao. (2023) A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future Oncology 19:11, pages 753-761.
Crossref
Crossref
Srdan Verstovsek, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman & Ruben A Mesa. (2022) SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncology 18:27, pages 2999-3009.
Crossref
Crossref
John Mascarenhas, Francesco Passamonti, Kate BurburyTarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin WondeCandice Jamois, Bruno KovicLing-Yuh HuwSudhakar KatakamMargherita MaffioliRuben Mesa, Jeanne PalmerMarta BelliniDavid M. Ross, Alessandro M. Vannucchi & Abdulraheem Yacoub. (2022) The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances 6:4, pages 1162-1174.
Crossref
Crossref
Louisa Liu, Neil Dudheker, Lhara M Sumarriva Lezama, Sameer Shah, Maureen Nwaokoro & Vishal Ranpura. (2021) Transformation of Polycythemia Vera to Pure Erythroid Leukemia. Cureus.
Crossref
Crossref
Naveen Pemmaraju, Natalie C. Chen & Srdan Verstovsek. (2021) Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America 35:2, pages 409-429.
Crossref
Crossref
Akbar Dorgalaleh, Mehran Bahraini & Sayed Esmaeil Ahmadi. 2021. Personalized Medicine in Anesthesia, Pain and Perioperative Medicine. Personalized Medicine in Anesthesia, Pain and Perioperative Medicine
231
274
.
Martin Griesshammer, Jean-Jacques Kiladjian & Carlos Besses. (2019) Thromboembolic events in polycythemia vera. Annals of Hematology 98:5, pages 1071-1082.
Crossref
Crossref
Francesca Palandri, Elena Sabattini & Margherita Maffioli. (2018) Treating early-stage myelofibrosis. Annals of Hematology 98:2, pages 241-253.
Crossref
Crossref
Antónia Hatalova, Jiri Schwarz, Mirjana Gotic, Miroslav Penka, Mikulas Hrubisko, Rajko Kusec, Miklós Egyed, Martin Griesshammer, Maria Podolak-Dawidziak, Andrzej Hellmann, Sergiy Klymenko, Emilia Niculescu-Mizil, Petro E. Petrides, Sebastian Grosicki, Matjaz Sever, Nathan Cantoni, Jürgen Thiele, Dominik Wolf & Heinz Gisslinger. (2018) Recommendations for the diagnosis and treatment of patients with polycythaemia vera. European Journal of Haematology 101:5, pages 654-664.
Crossref
Crossref
Claire N. HarrisonAdam J. MeadAnesh PanchalSonia FoxChristina YapEmmanouela GbandiAimee HoultonSamah AlimamJoanne EwingMarion WoodFrederick ChenJason CoppellNicki PanoskaltsisSteven KnapperSahra AliAngela HamblinRobyn ScherberAmylou C. DueckNicholas C. P. Cross, Ruben MesaMary Frances McMullin. (2017) Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130:17, pages 1889-1897.
Crossref
Crossref
Samah Alimam & Claire Harrison. (2017) Experience with ruxolitinib in the treatment of polycythaemia vera. Therapeutic Advances in Hematology 8:4, pages 139-151.
Crossref
Crossref
Andreas Reiter & Claire Harrison. (2016) How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Current Hematologic Malignancy Reports 11:5, pages 356-367.
Crossref
Crossref
Shreekant Parasuraman, Marco DiBonaventura, Kelly Reith, Ahmad Naim, Kristen Concialdi & Nicholas J. Sarlis. (2016) Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Experimental Hematology & Oncology 5:1.
Crossref
Crossref
Giovanni Barosi. (2015) Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. Clinical Investigation 5:7, pages 643-651.
Crossref
Crossref
Martin Griesshammer, Heinz Gisslinger & Ruben Mesa. (2015) Current and future treatment options for polycythemia vera. Annals of Hematology 94:6, pages 901-910.
Crossref
Crossref
Yoshiyasu Kono, Akinobu Takaki, Hideo Gobara, Ken-ichi Matsuoka, Masato Nishino, Hiroyuki Okada & Kazuhide Yamamoto. (2015) Polycythemia Vera Diagnosed after Esophageal Variceal Rupture. Internal Medicine 54:18, pages 2395-2399.
Crossref
Crossref